Multipotent mesenchymal stromal/stem cell-based therapies for acute respiratory distress syndrome: current progress, challenges, and future frontiers

Sababathy, M.; Ramanathan, G.; Ganesan, S.; Sababathy, S.; Yasmin, A.R.; Ramasamy, R.; Foo, J.B.; Looi, Q.H.; Nur-Fazila, S.H.

Sababathy, M.; Ramanathan, G.; Ganesan, S.; Sababathy, S.; Yasmin, A.R.; Ramasamy, R.; Foo, J.B.; Looi, Q.H.; Nur-Fazila, S.H..

Afiliação

Sababathy, M.; University Putra Malaysia. Faculty of Veterinary Medicine. Department of Veterinary Pathology and Microbiology. Serdang. MY
Ramanathan, G.; University Malaya. Faculty of Computer Science and Information Technology. Kuala Lumpur. MY
Ganesan, S.; Management and Science University. School of Pharmacy. Shah Alam. MY
Sababathy, S.; National Defence University of Malaysia. Faculty of Medicine and Defence Health. Sungai Besi. MY
Yasmin, A.R.; University Putra Malaysia. Faculty of Veterinary Medicine. Department of Veterinary Laboratory Diagnostics. Serdang. MY
Ramasamy, R.; University Putra Malaysia. Faculty of Medicine and Health Sciences. Department of Pathology. Serdang. MY
Foo, J.B.; Taylors University. Faculty of Health and Medical Sciences. Center for Drug Discovery and Molecular Pharmacology (CDDMP). Subang Jaya. MY
Looi, Q.H.; My Cytohealth Sdn. Bhd.. Bandar Seri Petaling. MY
Nur-Fazila, S.H.; University Putra Malaysia. Faculty of Veterinary Medicine. Department of Veterinary Pathology and Microbiology. Serdang. MY

Braz. j. med. biol. res ; 57: e13219, fev.2024. graf

Article em En | LILACS-Express | LILACS | ID: biblio-1574230

Biblioteca responsável: BR1.1

ABSTRACT

ABSTRACT

Acute respiratory distress syndrome (ARDS) is a critical, life-threatening condition marked by severe inflammation and impaired lung function. Mesenchymal stromal/stem cells (MSCs) present a promising therapeutic avenue due to their immunomodulatory, anti-inflammatory, and regenerative capabilities. This review comprehensively evaluates MSC-based strategies for ARDS treatment, including direct administration, tissue engineering, extracellular vesicles (EVs), nanoparticles, natural products, artificial intelligence (AI), gene modification, and MSC preconditioning. Direct MSC administration has demonstrated therapeutic potential but necessitates optimization to overcome challenges related to effective cell delivery, homing, and integration into damaged lung tissue. Tissue engineering methods, such as 3D-printed scaffolds and MSC sheets, enhance MSC survival and functionality within lung tissue. EVs and MSC-derived nanoparticles offer scalable and safer alternatives to cell-based therapies. Likewise, natural products and bioactive compounds derived from plants can augment MSC function and resilience, offering complementary strategies to enhance therapeutic outcomes. In addition, AI technologies could aid in optimizing MSC delivery and dosing, and gene editing tools like CRISPR/Cas9 allow precise modification of MSCs to enhance their therapeutic properties and target specific ARDS mechanisms. Preconditioning MSCs with hypoxia, growth factors, or pharmacological agents further enhances their therapeutic potential. While MSC therapies hold significant promise for ARDS, extensive research and clinical trials are essential to determine optimal protocols and ensure long-term safety and effectiveness.

Palavras-chave

Acute respiratory distress syndrome; Gene modification; Multipotent mesenchymal stromal/stem cells; Preconditioning; Tissue engineering; Treatment strategy

Texto completo

Adicionar na Minha BVS

Imprimir

XML

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: LILACS Idioma: En Revista: Braz. j. med. biol. res Assunto da revista: BIOLOGIA / MEDICINA Ano de publicação: 2024 Tipo de documento: Article / Project document País de afiliação: Malásia País de publicação: Brasil

Texto completo

Adicionar na Minha BVS

Imprimir

XML

Buscar no Google